Daylight photodynamic therapy with methyl aminolevulinate cream as a convenient, similarly effective, nearly painless alternative to conventional photodynamic therapy in actinic keratosis treatment: a randomized controlled trial

Daylight photodynamic therapy (DL‐PDT) of actinic keratosis (AK) has shown preliminary efficacy and safety results comparable to conventional photodynamic therapy (c‐PDT), using methyl aminolevulinate (MAL) cream.

[1]  L. Naldi,et al.  Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: Results from the Prevalence of Actinic Keratoses Italian Study, 2003-2004. , 2006, Archives of dermatology.

[2]  J. McGregor,et al.  Guidelines for the management of actinic keratoses , 2007, The British journal of dermatology.

[3]  H. Wulf,et al.  Continuous activation of PpIX by daylight is as effective as and less painful than conventional photodynamic therapy for actinic keratoses; a randomized, controlled, single‐blinded study , 2008, The British journal of dermatology.

[4]  P Calzavara-Pinton,et al.  Daylight photodynamic therapy for actinic keratosis: an international consensus , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[5]  G. Martin.  A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½h in daylight-mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp , 2012 .

[6]  B. L. Andersen,et al.  A randomized, multicentre study of directed daylight exposure times of 1½ vs. 2½ h in daylight‐mediated photodynamic therapy with methyl aminolaevulinate in patients with multiple thin actinic keratoses of the face and scalp , 2011, The British journal of dermatology.

[7]  J. Bothwell,et al.  Prevalence of solar damage and actinic keratosis in a Merseyside population , 2000, The British journal of dermatology.

[8]  J. Q. Rosso,et al.  Photodynamic therapy of actinic keratoses with 8% and 16% methyl aminolaevulinate and home-based daylight exposure: a double-blinded randomized clinical trial , 2010 .

[9]  Data analysis of the Brazilian Society of Dermatology skin cancer prevention campaign , 1999 to 2005 * , 2022 .

[10]  C. Frost,et al.  Epidemiology of solar keratoses , 1994, The British journal of dermatology.

[11]  L. Braathen.  Daylight photodynamic therapy in private practice in Switzerland: gain without pain. , 2012, Acta dermato-venereologica.

[12]  J C Kennedy,et al.  Endogenous protoporphyrin IX, a clinically useful photosensitizer for photodynamic therapy. , 1992, Journal of photochemistry and photobiology. B, Biology.

[13]  Even Angell-Petersen,et al.  Porphyrin formation in actinic keratosis and basal cell carcinoma after topical application of methyl 5-aminolevulinate. , 2006, The Journal of investigative dermatology.

[14]  B. L. Andersen,et al.  Daylight‐mediated photodynamic therapy of moderate to thick actinic keratoses of the face and scalp: a randomized multicentre study , 2012, The British journal of dermatology.

[15]  A. Sidoroff,et al.  European guidelines for topical photodynamic therapy part 1: treatment delivery and current indications – actinic keratoses, Bowen’s disease, basal cell carcinoma , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.